NCT00396968View on ClinicalTrials.gov

AMD3100 With Busulfan, Fludarabine and Thymoglobulin for Allogeneic Stem Cell Transplant for AML and MDS

PHASE1/PHASE2WithdrawnINTERVENTIONAL
0
Timeline

Start Date

Not specified

Conditions
Acute Myelogenous LeukemiaMyelodysplastic Syndromes
Interventions
DRUG

AMD3100

PROCEDURE

Allogeneic Stem Cell Transplantation

Sponsors

Collaborators (1)

AnorMED
All Listed Sponsors
collaborator

AnorMED

INDUSTRY

lead

Genzyme, a Sanofi Company

INDUSTRY

NCT00396968 - AMD3100 With Busulfan, Fludarabine and Thymoglobulin for Allogeneic Stem Cell Transplant for AML and MDS | Biotech Hunter | Biotech Hunter